Want to join the conversation?
$AMGN said its Phase 3 GAUSS-3 trial evaluating drug Repatha (evolocumab) in patients with high cholesterol, who cannot tolerate statins, met its co-primary endpoints. GAUSS-3 is a three-part trial that is evaluating the safety, tolerability and efficacy of Repatha.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.